Acorda Therapeutics, Inc. stock performance trend indicates that the stock price has rallied 47.93% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 28.59% . Looking at the past 52 week period, the stock price is up at 1.59% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Acorda Therapeutics, Inc. has a negative value of -20.7 compared to overall market performance.Acorda Therapeutics, Inc. is having a Relative Strength Index of 53.18 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) has tumbled 4.62% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 6.13% in the last four weeks. The stocks have underperformed the S&P 500 by 4.84% during the past week but Acorda Therapeutics, Inc. (NASDAQ:ACOR) it has outperformed the index in 4 weeks by 4.92%.
For the current week, the company shares have a recommendation consensus of Buy. Acorda Therapeutics, Inc. (NASDAQ:ACOR) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.85 points or 3.07% at $26.85 with 1,628,484 shares getting traded. Post opening the session at $27.25, the shares hit an intraday low of $26.6 and an intraday high of $27.8 and the price was in this range throughout the day. The company has a market cap of $1,246 million and the number of outstanding shares has been calculated to be 46,407,850 shares. The 52-week high of Acorda Therapeutics, Inc. (NASDAQ:ACOR) is $33 and the 52-week low is $16.4.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Acorda Therapeutics Inc was Upgraded by Goldman to Neutral on Feb 15, 2017.
Company has reported several Insider transactions to the SEC, on Feb 13, 2017, Jane Wasman (President, Intl and GC) sold 54,536 shares at 22.30 per share price.On Feb 13, 2017, David Lawrence (Chief, Bus. Ops & PAO) sold 63,183 shares at 22.33 per share price.On Feb 13, 2017, Barry E Greene (director) sold 723 shares at 22.65 per share price.
Acorda Therapeutics Inc Last issued its quarterly earnings results on Feb 14, 2017. The company reported $0.05 EPS for the quarter, missing the analyst consensus estimate by $ -0.16. Analyst had a consensus of $0.21. The company had revenue of $134.00 million for the quarter, compared to analysts expectations of $139.67 million. The companys revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.28 EPS.
Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Companys lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.